The U.S. Food and Drug Administration (FDA) has asked industry
and other parties for information on issues related to developing
medical devices, drugs, and biologic products to treat and prevent
osteoarthritis (OA). The agency will use the information to
finalize a draft guidance issued in July 1999 to help sponsors
develop new products for OA.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
